Weekly Digest – September 2024 Weekly Digest – September 2024 24 Sep 2024: Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) Araris Biotech has […]
Weekly Digest – September 2024 Weekly Digest – September 2024 23 Sep 2024: AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble AstraZeneca and Daiichi Sankyo’s Dato-DXd missed its overall survival goal in […]
Weekly Digest – September 2024 Weekly Digest – September 2024 23 Sep 2024: Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors Innate Pharma has received FDA clearance for its […]
Weekly Digest – September 2024 Weekly Digest – September 2024 24 Sep 2024: Pinotbio Secures Milestone Payment Following Celltrion’s Execution of ADC Platform Technology Option Pinotbio is set to receive a milestone payment from Celltrion after the latter chose to […]
Weekly Digest – September 2024 Weekly Digest – September 2024 24 Sep 2024: FDA Grants Fast Track Status to EO-3021 for CLDN18.2-Expressing Gastric or GEJ Cancer EO-3021 (SYSA1801) has received fast track designation for advanced or metastatic CLDN18.2-expressing gastric or […]
